Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  SciClone Pharmaceuticals, Inc.    SCLN

News SummaryMost relevantAll newsSector news 

SciClone to Restate Results for Certain Periods on China Accounting Errors

share with twitter share with LinkedIn share with facebook
share via e-mail
02/22/2013 | 11:05pm CET
   By Debbie Cai 

SciClone Pharmaceuticals Inc. (>> SciClone Pharmaceuticals, Inc.) said it will restate its financial statements for certain periods in 2012 and 2011 due mainly to accounting errors at a Chinese subsidiary.

Shares slid 6.2% to $4.52 after hours Friday. The stock is up 12% so far this year.

Chinese drugmaker NovaMed Pharmaceuticals Inc., which SciClone acquired in April 2011, made accounting errors pertaining to the timing of Pfizer Inc. (>> Pfizer Inc.) product-revenue recognition and the recognition of product-return reserves as to antiplatelet drug Aggrastat.

The company will restate financial statements for the first, second and third quarters of last year, the second and third quarters of 2011, and for the full 2011.

SciClone Chief Executive Friedhelm Blobel said the decision to restate financials, which is expected to increase the company's 2012 revenue and earnings and decrease that of 2011, was made after careful review of available facts.

The company believes the changes will raise its revenue for the first nine months of last year by about $3 million, and increase its profit before income taxes by about $2 million. The changes for the full 2011 will lower revenue by about $1 million and decrease income by less than $1 million.

SciClone also said the goodwill related to the acquisition of NovaMed will be increased by approximately $2 million. The restatements wouldn't impact previously reported cash or cash equivalents balances, the company said.

The company said it plans to amend its 2011 10-K form and other relevant filings as soon as reasonably practicable.

Last November, SciClone said it swung to a third-quarter loss as the company works to address issues across its China organization, some of which might have affected sales of its lead drug Zadaxin.

Write to Debbie Cai at debbie.cai@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SciClone Pharmaceuticals, Inc., Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
11/22 SCICLONE PHARMACEUTICALS : Confirms Receipt Of Unsolicited Proposal From GL Capi..
11/17 SCICLONE PHARMACEUTICALS : Reports Third Quarter 2016 Financial Results
11/15 SCICLONE PHARMACEUTICALS : Research Reports Initiation on Drug Makers Stocks -- ..
11/14 SCICLONE PHARMACEUTICALS : Confirms Receipt Of Unsolicited Proposal From GL Capi..
11/09 SCICLONE PHARMACEUTICALS : posts 3Q profit
11/09 SCICLONE PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
11/09 SCICLONE PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
11/09 SCICLONE PHARMACEUTICALS : Reports Third Quarter 2016 Financial Results
11/09 SCICLONE PHARMACEUTICALS : To Report Third Quarter 2016 Financial Results On Nov..
11/03 SCICLONE PHARMACEUTICALS : To Report Third Quarter 2016 Financial Results On Nov..
More news
Sector news : Pharmaceuticals - NEC
12/09 FTSE records best week since July, Sky surges 27 percent on Fox bid
12/09DJASTRAZENECA : FDA Accepts License Application for Durvalumab
12/09DJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11/20 WEEK IN REVIEW : Week's China Life Science Deals Total $795 Million
11/11 SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q3 2016 Results - Ea..
11/09 SciClone Pharmaceuticals reports Q3 results
11/09 VALUATION DASHBOARD : Healthcare - Update
10/02 WEEK IN REVIEW : Big Week For Cross-Border Life Science Deals
Duration : Period :
SciClone Pharmaceuticals,  Technical Analysis Chart | SCLN | US80862K1043 | 4-Traders
Full-screen chart
Technical analysis trends SCICLONE PHARMACE...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Friedhelm Blobel President, Chief Executive Officer & Director
Jon Sheldon Saxe Chairman
Wai-Shun Wilson Cheung Chief Financial Officer, Secretary & SVP-Finance
Rick J. Hawkins Independent Director
Gregg Anthony Lapointe Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.29%305 407
ROCHE HOLDING LTD.-17.58%193 824
PFIZER INC.-4.15%192 367
NOVARTIS AG-18.49%182 959
MERCK & CO., INC.15.92%168 820
More Results